



Domain Therapeutics strengthens its intellectual property for its series of Treg depleting anti-CCR8 antibodies, including best-in-class candidate DT-7012

- *Recent publication of three international Patent Cooperation Treaty (PCT) patent applications covering Domain's series of Treg depleting anti-CCR8 antibodies.*
- *Three new patents expand geographic protection of the Company's best-in-class CCR8 asset.*
- *Depletion of T regulatory cells via CCR8, a GPCR target specific to these cell types in the tumor microenvironment, is a highly strategic approach in immuno-oncology to improve clinical outcomes in cancer patients.*

Strasbourg, France – Montreal, Canada - Boston, United States June 6, 2024 – Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptor (GPCR) driven immuno-resistance, today announces the publication of three international PCT patent applications.

These patents will significantly strengthen the Company's intellectual property protection for its series of tumor-infiltrating regulatory T cells (Tregs) depleting antibody-dependent cell-mediated cytotoxicity/phagocytosis (ADCC/ADCP) anti-CCR8 antibodies, including [DT-7012](#), a novel drug candidate with best-in-class potential compared to other clinical-stage CCR8 antibodies. Currently in the pre-IND stage of development, DT-7012 is set to commence Phase I clinical trials in early 2025.

Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: “These three new patents are pivotal to our strategy, enhancing our robust patent estate and expanding our reach across diverse market opportunities. They underscore the broad international application of our Treg depleting ADCC/ADCP anti-CCR8 antibodies, particularly for our lead anti-CCR8 candidate DT-7012. They also reinforce Domain's position as an industry leader in GPCR-mediated immunotherapies. Notably, this timely publication of PCT patent applications aligns with our accelerated and broadened research and development efforts in immuno-oncology.”

CCR8 is a GPCR target specifically expressed by tumor infiltrating Tregs, major immunosuppressive cells responsible for the failure of several therapeutics in the clinic, which makes this target highly strategic for the development of efficient novel immunotherapies.

-ENDS-

For more information, please contact:

ICR Consilium

Amber Fennell, Namrata Taak, Jonathan Edwards

Email: DomainTherapeutics@consilium-comms.com

Tel: +44 (0)20 3709 5813

Yucatan (for French media)
Annie-Florence Loyer
Email: AFloyer@yucatan.fr
Tel: +33 (0)6.88.20.35.59

About Domain Therapeutics

Domain Therapeutics, a global clinical-stage biopharmaceutical company, is developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes but still underexploited in immuno-oncology, to unlock new possibilities in cancer. As the leading GPCRs immuno-oncology company, Domain aims to beat resistance to immune modulation within the tumor microenvironment by establishing the therapeutic potential of GPCRs to defeat cancer. Two decades of solid track record in GPCR drug discovery, validated through multiple pharma partnerships across various therapeutic areas and associated to a world-class drug discovery platform, has enabled the Company to deliver the next generation of GPCR targeting immunotherapies to patients.

Domain's proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The Company also has an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain's proprietary cross-validation drug discovery and development platform.

Since 2022, the Company raised €51m (\$55m) in series A to progress preclinical and clinical development of its high-value drug candidates to address GPCR-mediated immunosuppression. Domain is supported by leading international venture capital firms from Europe (3B Future Health Fund, Seventure, Schrodgers, Omnes, Turenne, Theodorus), Asia (Panacea and Viva) and North America (CTI Life Science, adMare).

About DT-7012

DT-7012 is a novel anti-CCR8 monoclonal antibody (mAb) depleting tumor-infiltrating Tregs (major immunosuppressive cells). This antibody reduces Treg population within the tumor microenvironment by leveraging antibody-dependent cell-mediated cytotoxicity/phagocytosis (ADCC/ADCP) mechanisms. Treg depletion with anti-CCR8 mAb has demonstrated a unique anti-tumor potency as a monotherapy. DT-7012 has a proven best-in-class potential compared to other clinical-stage CCR8 antibodies, paving the way for effective GPCR-targeting immunotherapies, aiming to activate antitumor immunity for cancer patients unresponsive to other treatments.

Phase I clinical studies of DT-7012 are expected to start in early 2025 for solid tumors and mid-2025 for cutaneous T-cell lymphoma (CTCL). In preparation for these pivotal trials, Domain had signed a manufacturing agreement in March 2024 with Chime Biologics, a leading Contract Development and Manufacturing Organization.